Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Dec;64(12):5042–5046. doi: 10.1128/iai.64.12.5042-5046.1996

Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci.

J G Vallejo 1, C J Baker 1, M S Edwards 1
PMCID: PMC174486  PMID: 8945544

Abstract

Group B streptococci (GBS) are the major cause of sepsis and fatal shock in neonates in the United States. The precise role of tumor necrosis factor alpha (TNF-alpha) in the development of human GBS sepsis has not been defined; however, whole GBS have been shown to induce the production of this inflammatory cytokine. We sought to determine which bacterial cell wall components of GBS are responsible for triggering TNF-alpha production. Human cord blood monocytes were stimulated with encapsulated (COH1) or unencapsulated (COH1-13) whole type III GBS or with purified bacterial components, including type III capsular polysaccharide (III-PS), group B polysaccharide (GB-PS), lipoteichoic acid (LTA), or peptidoglycan (PG). Lipopolysaccharide from Escherichia coli served as a control. Supernatants were harvested at specific timed intervals, and TNF-alpha levels were measured by enzyme-linked immunosorbent assay. Monocytes exposed to COH1 and COH1-13 induced similar amounts of TNF-alpha. III-PS, GB-PS, LTA, and PG each induced TNF-alpha in a time- and concentration-dependent manner. However, TNF-alpha release was significantly greater after stimulation by the GB-PS or PG than after stimulation by III-PS or LTA (P < 0.05). Our findings indicate that GB-PS and PG are the bacterial cell wall components primarily evoking TNF-alpha release. These, alone or in concert with other factors, may be responsible for septic shock accompanying GBS sepsis.

Full Text

The Full Text of this article is available as a PDF (226.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Edwards M. S., Kasper D. L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549. [PubMed] [Google Scholar]
  2. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L. Immunological investigation of infants with septicemia or meningitis due to group B Streptococcus. J Infect Dis. 1977 Aug;136 (Suppl):S98–104. doi: 10.1093/infdis/136.supplement.s98. [DOI] [PubMed] [Google Scholar]
  4. Bhakdi S., Klonisch T., Nuber P., Fischer W. Stimulation of monokine production by lipoteichoic acids. Infect Immun. 1991 Dec;59(12):4614–4620. doi: 10.1128/iai.59.12.4614-4620.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bone R. C. Gram-positive organisms and sepsis. Arch Intern Med. 1994 Jan 10;154(1):26–34. [PubMed] [Google Scholar]
  6. Casey L. C., Balk R. A., Bone R. C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993 Oct 15;119(8):771–778. doi: 10.7326/0003-4819-119-8-199310150-00001. [DOI] [PubMed] [Google Scholar]
  7. De Cueninck B. J., Shockman G. D., Swenson R. M. Group B, type III streptococcal cell wall: composition and structural aspects revealed through endo-N-acetylmuramidase-catalyzed hydrolysis. Infect Immun. 1982 Feb;35(2):572–581. doi: 10.1128/iai.35.2.572-581.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dulkerian S. J., Kilpatrick L., Costarino A. T., Jr, McCawley L., Fein J., Corcoran L., Zirin S., Harris M. C. Cytokine elevations in infants with bacterial and aseptic meningitis. J Pediatr. 1995 Jun;126(6):872–876. doi: 10.1016/s0022-3476(95)70199-0. [DOI] [PubMed] [Google Scholar]
  9. Gibson R. L., Redding G. J., Henderson W. R., Truog W. E. Group B streptococcus induces tumor necrosis factor in neonatal piglets. Effect of the tumor necrosis factor inhibitor pentoxifylline on hemodynamics and gas exchange. Am Rev Respir Dis. 1991 Mar;143(3):598–604. doi: 10.1164/ajrccm/143.3.598. [DOI] [PubMed] [Google Scholar]
  10. Givner L. B., Gray L., O'Shea T. M. Antibodies to tumor necrosis factor-alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats. Pediatr Res. 1995 Oct;38(4):551–554. doi: 10.1203/00006450-199510000-00013. [DOI] [PubMed] [Google Scholar]
  11. Heumann D., Barras C., Severin A., Glauser M. P., Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun. 1994 Jul;62(7):2715–2721. doi: 10.1128/iai.62.7.2715-2721.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ling E. W., Noya F. J., Ricard G., Beharry K., Mills E. L., Aranda J. V. Biochemical mediators of meningeal inflammatory response to group B streptococcus in the newborn piglet model. Pediatr Res. 1995 Dec;38(6):981–987. doi: 10.1203/00006450-199512000-00025. [DOI] [PubMed] [Google Scholar]
  14. Mancuso G., Tomasello F., Ofek I., Teti G. Anti-lipoteichoic acid antibodies enhance release of cytokines by monocytes sensitized with lipoteichoic acid. Infect Immun. 1994 Apr;62(4):1470–1473. doi: 10.1128/iai.62.4.1470-1473.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mancuso G., Tomasello F., von Hunolstein C., Orefici G., Teti G. Induction of tumor necrosis factor alpha by the group- and type-specific polysaccharides from type III group B streptococci. Infect Immun. 1994 Jul;62(7):2748–2753. doi: 10.1128/iai.62.7.2748-2753.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Marks J. D., Marks C. B., Luce J. M., Montgomery A. B., Turner J., Metz C. A., Murray J. F. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan;141(1):94–97. doi: 10.1164/ajrccm/141.1.94. [DOI] [PubMed] [Google Scholar]
  17. Marques M. B., Kasper D. L., Pangburn M. K., Wessels M. R. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992 Oct;60(10):3986–3993. doi: 10.1128/iai.60.10.3986-3993.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mattingly S. J., Johnston B. P. Comparative analysis of the localization of lipoteichoic acid in Streptococcus agalactiae and Streptococcus pyogenes. Infect Immun. 1987 Oct;55(10):2383–2386. doi: 10.1128/iai.55.10.2383-2386.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mattsson E., Rollof J., Verhoef J., Van Dijk H., Fleer A. Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors. Infect Immun. 1994 Sep;62(9):3837–3843. doi: 10.1128/iai.62.9.3837-3843.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mattsson E., Van Dijk H., Van Kessel K., Verhoef J., Fleer A., Rollof J. Intracellular pathways involved in tumor necrosis factor-alpha release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar. J Infect Dis. 1996 Jan;173(1):212–218. doi: 10.1093/infdis/173.1.212. [DOI] [PubMed] [Google Scholar]
  21. Michon F., Katzenellenbogen E., Kasper D. L., Jennings H. J. Structure of the complex group-specific polysaccharide of group B Streptococcus. Biochemistry. 1987 Jan 27;26(2):476–486. doi: 10.1021/bi00376a020. [DOI] [PubMed] [Google Scholar]
  22. Musher D. M., Verbrugh H. A., Verhoef J. Suppression of phagocytosis and chemotaxis by cell wall components of Staphylococcus aureus. J Immunol. 1981 Jul;127(1):84–88. [PubMed] [Google Scholar]
  23. Nealon T. J., Mattingly S. J. Kinetic and chemical analyses of the biologic significance of lipoteichoic acids in mediating adherence of serotype III group B streptococci. Infect Immun. 1985 Oct;50(1):107–115. doi: 10.1128/iai.50.1.107-115.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Payne N. R., Burke B. A., Day D. L., Christenson P. D., Thompson T. R., Ferrieri P. Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J. 1988 Dec;7(12):836–847. [PubMed] [Google Scholar]
  25. Peat E. B., Augustine N. H., Drummond W. K., Bohnsack J. F., Hill H. R. Effects of fibronectin and group B streptococci on tumour necrosis factor-alpha production by human culture-derived macrophages. Immunology. 1995 Mar;84(3):440–445. [PMC free article] [PubMed] [Google Scholar]
  26. Peterson P. K., Wilkinson B. J., Kim Y., Schmeling D., Douglas S. D., Quie P. G., Verhoef J. The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest. 1978 Mar;61(3):597–609. doi: 10.1172/JCI108971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Teti G., Mancuso G., Tomasello F., Chiofalo M. S. Production of tumor necrosis factor-alpha and interleukin-6 in mice infected with group B streptococci. Circ Shock. 1992 Oct;38(2):138–144. [PubMed] [Google Scholar]
  28. Teti G., Mancuso G., Tomasello F. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun. 1993 Jan;61(1):227–235. doi: 10.1128/iai.61.1.227-235.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Timmerman C. P., Mattsson E., Martinez-Martinez L., De Graaf L., Van Strijp J. A., Verbrugh H. A., Verhoef J., Fleer A. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun. 1993 Oct;61(10):4167–4172. doi: 10.1128/iai.61.10.4167-4172.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tuomanen E., Liu H., Hengstler B., Zak O., Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis. 1985 May;151(5):859–868. doi: 10.1093/infdis/151.5.859. [DOI] [PubMed] [Google Scholar]
  31. Tuomanen E., Rich R., Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis. 1987 Apr;135(4):869–874. doi: 10.1164/arrd.1987.135.4.869. [DOI] [PubMed] [Google Scholar]
  32. Tuomanen E., Tomasz A., Hengstler B., Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis. 1985 Mar;151(3):535–540. doi: 10.1093/infdis/151.3.535. [DOI] [PubMed] [Google Scholar]
  33. Verbrugh H. A., Van Dijk W. C., Peters R., Van Der Tol M. E., Verhoef J. The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. Immunology. 1979 Jul;37(3):615–621. [PMC free article] [PubMed] [Google Scholar]
  34. Waage A., Brandtzaeg P., Espevik T., Halstensen A. Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am. 1991 Dec;5(4):781–791. [PubMed] [Google Scholar]
  35. Wakabayashi G., Gelfand J. A., Jung W. K., Connolly R. J., Burke J. F., Dinarello C. A. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest. 1991 Jun;87(6):1925–1935. doi: 10.1172/JCI115218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Weidemann B., Brade H., Rietschel E. T., Dziarski R., Bazil V., Kusumoto S., Flad H. D., Ulmer A. J. Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures. Infect Immun. 1994 Nov;62(11):4709–4715. doi: 10.1128/iai.62.11.4709-4715.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wessels M. R., Paoletti L. C., Kasper D. L., DiFabio J. L., Michon F., Holme K., Jennings H. J. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov;86(5):1428–1433. doi: 10.1172/JCI114858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Williams P. A., Bohnsack J. F., Augustine N. H., Drummond W. K., Rubens C. E., Hill H. R. Production of tumor necrosis factor by human cells in vitro and in vivo, induced by group B streptococci. J Pediatr. 1993 Aug;123(2):292–300. doi: 10.1016/s0022-3476(05)81706-8. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES